TipRanks
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
Germany Market
VX1
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (VX1) Stock News & Sentiment

23 Followers
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
Premium
Ratings
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
8d ago
VRTX
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
Premium
Ratings
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
8d ago
VRTX
Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts
Premium
Weekend Updates
Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts
26d ago
NB
ACRS
Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors
Premium
Company Announcements
Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors
1M ago
VRTX
Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
Premium
Company Announcements
Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
1M ago
VRTX
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
Premium
Ratings
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
2M ago
VRTX
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
Premium
Market News
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
2M ago
SION
VRTX
More DE:VX1 News >

VX1 News on the Web

Capital Group Growth ETF (CGGR) Adds Nike and Apple on Monday
GuruFocus News
Neutral
2 Healthcare Stocks That Just Delivered Great News for Investors
The Motley Fool
Bullish
Scotiabank Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
TipRanks News
Bullish
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Celldex (CLDX) and Vertex Pharmaceuticals (VRTX)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)
TipRanks News
Neutral
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
The Motley Fool
Neutral
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Zacks
Neutral
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
The Motley Fool
Neutral

News Score - Last 7 Days

Positive
DE:VX1
Sector Average
Media Buzz
This Week9 articles
Weekly Average14.75 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:VX1’s Media Buzz Sentiment?
9 articles about DE:VX1 were published this week. In an average week, 14.75 articles are published.
    What is DE:VX1’s weekly average amount of articles?
    In an average week, 14.75 articles about DE:VX1 are published.
      What is DE:VX1’s News Sentiment?
      100% of articles about DE:VX1 were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        SMMTSummit Therapeutics
        CDNACareDx
        ARGXArgenx Se
        MEOBFMesoblast Limited
        KODKodiak Sciences
        Showing the stocks with the most bullish news sentiment over the past week